Lilly expects US Medicare to reverse course, fully cover Alzheimer's drugs

Eli Lilly and Co (LLY.N) expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer's drugs as more evidence emerges in coming weeks showing that clearing amyloid brain plaques can help patients, a company executive told Reuters.